Julian Teare

Julian Teare

Auto-generated profile, based on publicly available information

Julian Teare

Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2017 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
JAJames L. Alexander
James L. Alexander
Ian WilsonIan Wilson
Ian Wilson
JTJulian Teare
Julian Teare
JMJulian Marchesi
Julian Marchesi
JNJeremy Nicholson
Jeremy Nicholson
JKJames M. Kinross
James M. Kinross

21 December 2006 in Gut
Verified
Journal Article
Closed access
Julie CornishJulie Cornish
Julie Cornish
ETE Tan
E Tan
JTJ Teare
J Teare
TTT G Teoh
T G Teoh
RRR Rai
R Rai
PTP P Tekkis
P P Tekkis
Background: Inflammatory bowel disease (IBD) has a typical onset during the peak reproductive years. Evidence of the risk of adverse pregnancy outcomes in IBD is important for the management of pregnancy to assist in its management. Aim: To provide a clear assessment of risk of adverse outcomes during pregnancy in women with IBD. Design: The Medline literature was searched to identify studies reporting outcomes of pregnancy in patients with IBD. Random-effect meta-analysis was used to compare outcomes between women with IBD and normal controls. Patients and setting: A total of 3907 patients with IBD (Crohn’s disease 1952 (63%), ulcerative colitis 1113 (36%)) and 320 531 controls were reported in 12 studies that satisfied the inclusion criteria. Results: For women with IBD, there was a 1.87-fold increase in incidence of prematurity (<37 weeks gestation; 95% CI 1.52 to 2.31; p<0.001) compared with controls. The incidence of low birth weight (<2500 g) was over twice that of normal controls (95% CI 1.38 to 3.19; p<0.001). Women with IBD were 1.5 times more likely to undergo caesarean section (95% CI 1.26 to 1.79; p<0.001), and the risk of congenital abnormalities was found to be 2.37-fold increased (95% CI 1.47 to 3.82; p<0.001). Conclusion: The study has shown a higher incidence of adverse pregnancy outcomes in patients with IBD. Further studies are required to clarify which women are at higher risk, as this was not determined in the present study. This has an effect on the management of patients with IBD during pregnancy, who should be treated as a potentially high-risk group.

1 April 2007 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
ARAlexander C. von Roon
Alexander C. von Roon
LKLeonidas Karamountzos
Leonidas Karamountzos
SPSanjay Purkayastha
Sanjay Purkayastha
GRGeorge E. Reese
George E. Reese
ADAra W. Darzi
Ara W. Darzi
PTParis P. Tekkis
Paris P. Tekkis
Fecal calprotectin (FC) is a relatively new marker of intraluminal intestinal inflammation. Using meta-analytical techniques, the study aimed to evaluate the diagnostic precision of FC for inflammatory bowel disease (IBD) and colorectal cancer (CRC) in adults and children. Quantitative meta-analysis was performed on prospective studies, comparing FC levels against the histological diagnosis. Sensitivity, specificity, and diagnostic odds ratio (DOR) were calculated for each study. Summary receiver-operating characteristic (sROC) curves and subgroup analysis were undertaken. Study quality and heterogeneity were evaluated. Thirty studies of 5,983 patients were included. FC levels in patients with IBD were higher by 219.2 micrograms per gram (μg/g) compared with normal patients (P < 0.001). sROC curve analysis showed a sensitivity of 0.95 (95% CI 0.93–0.97), specificity of 0.91 (95% CI 0.86–0.91), and an area under the curve (AUC) of 0.95 for the diagnosis of IBD. Patients with colorectal neoplasia had nonsignificantly higher FC levels by 132.2 μg/g compared with noncancer controls (P = 0.18). Sensitivity and specificity of FC for the diagnosis of CRC were 0.36 and 0.71, respectively, with an AUC of 0.66. The diagnostic precision of FC for IBD was higher in children than adults with better accuracy at a cutoff level of 100 μg/g versus 50 μg/g. Sensitivity analysis and metaregression analysis did not significantly alter the results. FC cannot be recommended as a screening test for CRC in the general population. FC appeared to offer a good diagnostic precision in distinguishing IBD from non-IBD diagnoses, with higher precision at a cutoff of 100 μg/g.

1 June 2007 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
ARAlexander C. von Roon
Alexander C. von Roon
GRGeorge Reese
George Reese
JTJulian Teare
Julian Teare
VCVasilis Constantinides
Vasilis Constantinides
ADAra W. Darzi
Ara W. Darzi
PTParis P. Tekkis
Paris P. Tekkis
The risk of cancer in patients with Crohn's disease is not well defined. Using meta-analytical techniques, the present study was designed to quantify the risk of intestinal, extraintestinal, and hemopoietic malignancies in such patients. A literature search identified 34 studies of 60,122 patients with Crohn's disease. The incidence and relative risk of cancer were calculated for patients with Crohn's disease and compared with the baseline population of patients without Crohn's disease. Overall pooled estimates, with 95 percent confidence intervals, were obtained, using a random-effects model. The relative risk of small bowel, colorectal, extraintestinal cancer, and lymphoma compared with the baseline population was 28.4 (95 percent confidence interval, 14.46-55.66), 2.4 (95 percent confidence interval, 1.56-4.36), 1.27 (95 percent confidence interval, 1.1-1.47), and 1.42 (95 percent confidence interval, 1.16-1.73), respectively. On subgroup analysis, patients with Crohn's disease had an increased risk of colon cancer (relative risk, 2.59; 95 percent confidence interval, 1.54-4.36) but not of rectal cancer (relative risk, 1.46; 95 percent confidence interval, 0.8-2.55). There was significant association between the anatomic location of the diseased bowel and the risk of cancer in that segment. The risk of small bowel cancer and colorectal cancer was found to be higher in North America and the United Kingdom than in Scandinavian countries with no evidence of temporal changes in the cancer incidence. The present meta-analysis demonstrated an increased risk of small bowel, colon, extraintestinal cancers, and lymphoma in patients with Crohn's disease. Patients with extensive colonic disease that has been present from a young age should be candidates for endoscopic surveillance; however, further data are required to evaluate the risk of neoplasia over time.

1 September 2008 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
Julie CornishJulie Cornish
Julie Cornish
ETE. Tan
E. Tan
CSC. Simillis
C. Simillis
SCS.K. Clark
S.K. Clark
JTJ. Teare
J. Teare
PTParis P. Tekkis
Paris P. Tekkis
Several environmental and genetic factors have been implicated to date in the development of Crohn's disease (CD) and ulcerative colitis (UC). The aim of this study was to provide a quantification of the risk of oral contraceptive pill (OCP) use in the etiology of inflammatory bowel disease. A literature search was performed to identify comparative studies reporting on the association of oral contraceptive use in the etiology of UC and CD between 1983 and 2007. A random-effect meta-analysis was used to compare the incidence of UC or CD between the patients exposed to the OCP and nonexposed patients. The results were adjusted for smoking. A total of 75,815 patients were reported on by 14 studies, with 36,797 exposed to OCP and 39,018 nonexposed women. The pooled relative risk (RR) for CD for women currently taking the OCP was 1.51 (95% confidence interval [CI] 1.17–1.96, P = 0.002), and 1.46 (95% CI 1.26–1.70, P < 0.001), adjusted for smoking. The RR for UC in women currently taking the OCP was 1.53 (95% CI 1.21–1.94, P = 0.001), and 1.28 (95% CI 1.06–1.54, P = 0.011), adjusted for smoking. The RR for CD increased with the length of exposure to OCP. Moreover, although the RR did not reduce once the OCP was stopped, it was no longer significant once the OCP was stopped (CI contains 1), both for CD and for UC. This study provides evidence of an association between the use of oral contraceptive agents and development of IBD, in particular CD. The study also suggests that the risk for patients who stop using the OCP reverts to that of the nonexposed population.

1 April 2013 in The Lancet
Verified
Journal Article
Closed access
WAWendy Atkin
Wendy Atkin
EDEdward Dadswell
Edward Dadswell
KWKate Wooldrage
Kate Wooldrage
IKInes Kralj-Hans
Ines Kralj-Hans
CWChristian von Wagner
Christian von Wagner
SHSteve Halligan
Steve Halligan